Cypress Capital Group Sells 9,607 Shares of Hologic, Inc. (NASDAQ:HOLX)

Cypress Capital Group trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 75.9% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,050 shares of the medical equipment provider’s stock after selling 9,607 shares during the quarter. Cypress Capital Group’s holdings in Hologic were worth $226,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. iA Global Asset Management Inc. purchased a new position in shares of Hologic during the 1st quarter worth about $37,000. Mather Group LLC. bought a new position in shares of Hologic during the first quarter valued at approximately $48,000. Massmutual Trust Co. FSB ADV lifted its stake in shares of Hologic by 24.7% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock worth $54,000 after acquiring an additional 137 shares during the last quarter. Toth Financial Advisory Corp boosted its holdings in Hologic by 81.1% during the 1st quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider’s stock valued at $60,000 after acquiring an additional 347 shares during the period. Finally, Fidelis Capital Partners LLC purchased a new position in Hologic during the 1st quarter valued at $63,000. Institutional investors own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on HOLX. Needham & Company LLC reiterated a “buy” rating and set a $90.00 target price on shares of Hologic in a research report on Tuesday, July 30th. StockNews.com cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 10th. Stephens reaffirmed an “overweight” rating and set a $92.00 target price on shares of Hologic in a research report on Tuesday, July 30th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $82.00 price target on shares of Hologic in a report on Friday, August 16th. Finally, JPMorgan Chase & Co. lifted their target price on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $87.60.

Insider Buying and Selling at Hologic

In related news, CEO Stephen P. Macmillan sold 3,672 shares of the stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total value of $294,237.36. Following the transaction, the chief executive officer now owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, Director Christiana Stamoulis sold 9,039 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the sale, the director now directly owns 45,472 shares of the company’s stock, valued at $3,615,024. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Stephen P. Macmillan sold 3,672 shares of the company’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,280 shares of company stock worth $1,469,973. 1.75% of the stock is currently owned by insiders.

Hologic Stock Up 0.2 %

HOLX stock traded up $0.16 during trading on Friday, reaching $80.25. 1,106,135 shares of the company traded hands, compared to its average volume of 1,648,404. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.29 and a current ratio of 3.99. The company has a market capitalization of $18.73 billion, a price-to-earnings ratio of 40.94, a price-to-earnings-growth ratio of 2.64 and a beta of 0.99. The business has a 50 day simple moving average of $77.75 and a 200 day simple moving average of $76.14. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the prior year, the company posted $0.93 earnings per share. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, equities research analysts anticipate that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.